Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Erasca, Inc. (ERAS : NSDQ)

• Company Description    Erasca Inc. is a clinical-stage precision oncology company singularly focused on discovering, developing and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Erasca Inc. is based in SAN DIEGO. Number of Employees: 123

• Price / Volume Information    Yesterday's Closing Price: $5.99 Daily Weekly Monthly 20 Day Moving Average: 500,753 shares Shares Outstanding: 121.86 (millions) Market Capitalization: $729.93 (millions) Beta: 52 Week High: $24.47 52 Week Low: $5.43 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -27.48% -20.54% 12 Week -48.05% -43.63% Year To Date -61.55% -54.28%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3115 MERRYFIELD ROW SUITE 300 - SAN DIEGO,CA 92121 USA ph: 858-465-6511 fax: - ir@erasca.com http://www.erasca.com

• General Corporate Information    Officers Jonathan E. Lim - Chief Executive Officer and Chairman David M. Chacko - Chief Financial Officer James A. Bristol - Director Bihua Chen - Director Julie Hambleton - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29479A108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/25/22 Share - Related Items Shares Outstanding: 121.86 Most Recent Split Date: (:1) Beta: Market Capitalization: $729.93 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.34 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.44 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 11.16% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/25/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.72 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -19.23% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -40.20 12/31/21 - -52.48 09/30/21 - - ROA 03/31/22 - -28.56 12/31/21 - -33.58 09/30/21 - - Current Ratio 03/31/22 - 18.86 12/31/21 - 15.92 09/30/21 - 25.13 Quick Ratio 03/31/22 - 18.86 12/31/21 - 15.92 09/30/21 - 25.13 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 3.48 12/31/21 - 3.77 09/30/21 - 3.98 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©